-transparent.png){kind=logo}
Polycystic ovarian disease represents a poorly defined spectrum of clinical disorders having oligo-ovulation or anovulation as a common feature. There is no single, universally accepted biochemical or clinical definition. Clinical findings usually include anovulation resulting in irregular uterine bleeding and infertility, androgen excess resulting in hirsutism and acne, and obesity. The patho-physiology involves altered functions of the hypothalamus, pituitary, ovary and adrenal glands, resulting in failure of folliculogenesis to regularly proceed to ovulation. The cause of the initiating event in this disease process remains enigmatic. Therapy for the various abnormalities in polycystic ovarian disease is tailored to a patient's needs and may include preventing endometrial hyperplasia, controlling irregular uterine bleeding, controlling hirsutism and inducing ovulation.
E Schriock, and
M C Martin, and
R B Jaffe
December 1988,
Endocrinology and metabolism clinics of North America,
E Schriock, and
M C Martin, and
R B Jaffe
December 1987,
Obstetrics and gynecology clinics of North America,
E Schriock, and
M C Martin, and
R B Jaffe
August 1976,
British journal of obstetrics and gynaecology,
E Schriock, and
M C Martin, and
R B Jaffe
January 1991,
Annual review of medicine,
E Schriock, and
M C Martin, and
R B Jaffe
January 1984,
Obstetrics and gynecology annual,
E Schriock, and
M C Martin, and
R B Jaffe
June 1990,
Current opinion in obstetrics & gynecology,
E Schriock, and
M C Martin, and
R B Jaffe
April 1981,
Fertility and sterility,
E Schriock, and
M C Martin, and
R B Jaffe
December 1973,
Clinical obstetrics and gynecology,
E Schriock, and
M C Martin, and
R B Jaffe
September 1981,
Fertility and sterility,
E Schriock, and
M C Martin, and
R B Jaffe
January 1997,
Current therapy in endocrinology and metabolism,
